BOSTON, Nov. 17, 2020 /PRNewswire/ -- ConcertAI announced a multi-year collaboration with Novartis to advance research-grade real-world data (RWD) and advanced analytic technologies to support decision-making across the full scope of Novartis' oncology pipeline and portfolio. Under the collaboration, ConcertAI and Novartis will define characteristics of RWD that extend the insights traditionally gleaned from this source, bridging the space between traditional RWD and randomized controlled trials (RCT) by increasing RWD consistency, reliability, and veracity.
The work will also bring together the Novartis Oncology Center of Excellence, Digital, and Data42 teams with ConcertAI's eurekaHealth family of cloud real-world evidence (RWE) and AI technologies. By collaboratively advancing technologies to generate better insights, the discovery, development, and commercialization of transformative medicines can be accelerated for cancer patients worldwide. Early programs are focused on three key objectives:
- Improved RCT design based on RWE
- RWD-based label extensions & new indications
- Accelerated market access through improved patient insights and programs
"ConcertAI is pleased to be able to collaborate with Novartis in bringing forward the next generation of digital clinical solutions in oncology with the promise of accelerated innovations for healthcare providers and patients worldwide," said Jeff Elton, PhD, chief executive officer of ConcertAI. Dr. Elton went on to note, "Our commitments are absolute and relentlessly focused towards achieving new levels of performance in medical innovation and benefit for patients."
Adrian Cassidy, the head of RWE and data science at Novartis, said, "Novartis is a leading medicines company powered by advanced therapy platforms and data science committed to working with leading partners and disruptors in the industry as we reimagine medicine using RWD and AI technologies. ConcertAI has rapidly emerged as one of the most innovative RWD and AI companies in oncology and we are excited to embark on this important, multi-year collaboration."
ConcertAI is a leader in real-world evidence (RWE) and patient outcomes solutions for the biopharmaceutical and healthcare industries. ConcertAI has the leading real-world data (RWD) and enterprise RWE SaaS and AI solutions for oncology, and the world's top outcomes research and data science talent. Our singular mission is to partner with leading biopharma and healthcare providers to revolutionize clinical research and the patient therapeutic journey to realize the best possible outcomes. ConcertAI is a portfolio company of SymphonyAI, an operating group of leading companies that transform business with advanced AI and data solutions. eurekaHealth is a trademark of ConcertAI. For more information, visit us at www.concertai.com
Contact: Charu Gupta at [email protected]